Navigation Links
Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Teli
Date:5/15/2012

d a variable risk of transformation to acute myeloid leukemia.  It is estimated that MDS affects approximately 300,000 people worldwide.  According to the American Cancer Society, 10,000–20,000 new cases of MDS are diagnosed each year in the United States, with survival rates ranging from six months to six years.  MDS patients often require multiple blood transfusions to manage their disease.

Telintra has a novel mechanism of action that inhibits an enzyme called glutathione S-transferase P1-1, which leads to activation of Jun kinase, a key regulator of cellular growth and differentiation of blood precursor cells; this mechanism induces cancer cell death, or apoptosis, in human leukemia cell lines. Telintra is also being evaluated in a Phase 2 clinical trial in Revlimid refractory and resistant deletion 5q MDS patients and a Phase 2b clinical trial in non-deletion 5q MDS patients.  Additional information about Telintra is available at www.telik.com.

About Telik, Inc.

Telik, Inc. of Palo Alto, CA, is a clinical-stage drug development company focused on discovering and developing small-molecule drugs to treat cancer.  The company's most advanced drug candidate is Telintra, a modified glutathione analog intended for the treatment of hematologic disorders including myelodysplastic syndrome, followed by Telcyta®, a cancer-activated prodrug for the treatment of a variety of cancers.  Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small-molecule drug candidates.

This press release contains "forward-looking" statements regarding the future development of Telintra, the safety and effectiveness of Telintra in treating MDS, whether Telintra treatment results in hematologic improvement in patients with MDS, whether Telintra reduces the need for, or offer
'/>"/>

SOURCE Telik, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Telik Regains Compliance With Minimum Bid Price Requirement
2. Telik Announces Fourth Quarter and 2011 Year End Financial Results and 2012 Financial Guidance
3. Telik Announces Presentation and Webcast at 14th Annual BIO CEO & Investor Conference
4. Telik Announces Telintra Clinical Presentations at the Annual Meeting of the American Society of Hematology
5. Telik Announces Third Quarter 2011 Financial Results
6. Telik Announces Publication of a Report of Complete Response of G-CSF Resistent Severe Idiopathic Chronic Neutropenia Following Treatment with Telintra®
7. Telik Announces Ezatiostat (Telintra®) Preclinical Presentation at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. Telik Announces Initiation of a Phase 2b Clinical Trial of Telintra® (Ezatiostat HCL) in Patients With Low to Intermediate-1 Risk Non-Deletion (5q) Myelodysplastic Syndrome
9. Telik Announces Publication in the Journal Cancer of a Phase 2 Randomized Multicenter Study of Two Extended Dosing Schedules of Oral Ezatiostat in Low to Intermediate-1 Risk Myelodysplastic Syndrome
10. Telik Announces First Quarter 2011 Financial Results
11. Telik Announces Presentation of New Data on the Characterization of Novel Ezatiostat (TELINTRA®, TLK199) Analogs at American Association for Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... DUBLIN , Oct. 17, 2014 ... of the "Research and Development Prospect of ... offering. Based on the 2013 ... Chinese government policies about dialysis industry and the ... in-depth research about dialysis industry segmentations. Moreover, it ...
(Date:10/17/2014)... Oct. 17, 2014 A victim of medical negligence ... doctor with a history of alcohol abuse, a physician ... on Prop 46 today, highlighting how Prop 46 will identify ... testing. The ad pictures a doctor drinking ... To ER."  Proposition 46 will enact the first law in ...
(Date:10/17/2014)...  Talyst, a market leader in pharmacy automation will ... Nashville, TN. The company will ... for onsite, remote medication dispensing. Talyst,s ... and securely dispense medication onsite, on demand. Remote dispensing ... that the correct medication gets to the correct patient ...
Breaking Medicine Technology:Research and Development Prospect of China Dialysis Market, 2014-2018 2Research and Development Prospect of China Dialysis Market, 2014-2018 3Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 2Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 3Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 4Talyst Exhibits at LeadingAge Annual Meeting 2
... 13, 2010 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ... third quarter of 2010 on Wednesday, October 20, 2010 at ... and chief executive officer, will lead the call. On the ... third quarter of 2010.   The call will ...
... Following recent FDA approvals for prostate cancer treatment ... the lives of men with advanced prostate cancer ... from Johnson & Johnson. The drug, which could reach the ... with the potential to change clinical practice by providing ...
Cached Medicine Technology:Amylin Pharmaceuticals to Webcast Third Quarter Results 2Robotic Prostatectomy Expert Dr. David Samadi, MD Discusses Prostate Cancer Treatment Drug Abiraterone 2
(Date:10/20/2014)... MA (PRWEB) October 20, 2014 ... sponsoring a booth at the American Foundation for Suicide ... 25th. The AFSP is a not-for-profit organization that hosts ... Net proceeds from these events are used to help ... but education and personal relationships as well. , ...
(Date:10/20/2014)... October 20, 2014 hc1.com today ... secure cloud solution that enables healthcare organizations of ... ultimate healthcare-specific customer relationship management (“CRM”) solution. , ... unique needs of the healthcare industry, the hc1 ... providers and patients by combining healthcare CRM, HIPAA-compliant ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Principle Business ... takes pride in manufacturing top-of-the-line absorbent products. The ... of its most popular brand, Tranquility® Premium Protection absorbent ... a new website, gave its packaging a new look, ... the brand message to the public. , The new ...
(Date:10/20/2014)... 2014 Succeed is proud to announce that ... participated in the Every Body Walk! campaign by ... project that encourages workers to be more active outside of ... which concluded at the end of September, was a friendly ... metro areas. Participating companies gave their staff pedometers and ...
(Date:10/20/2014)... Ohio (PRWEB) October 20, 2014 Unveiled at ... new Strategic Direction Scorecard conservatively estimates member hospital ROI on ... spent on dues, The Center provides $12.50 in value to ... is (Member Value – Member Dues)/Member Dues. , “This ... at this number and we think the methodology is really ...
Breaking Medicine News(10 mins):Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 2Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4
... FORT LAUDERDALE, Fla., Dec. 10 Synovics,Pharmaceuticals, Inc. (OTC ... further reduction of its debt by paying off the,last ... the sale of,additional Series C Convertible Redeemable Preferred Stock ... As previously reported in the ...
... MIAMI, Dec. 10 Todobebe, Inc., a leading ... today the roll out,of its website property "embarazo.com", ... URL in 1999, and the new site reinforces ... trusted,content for Spanish speaking families globally. , ...
... LLC (Prime),announces that it has been chosen by Blue ... pharmacy benefit management services, beginning,January 1, 2009. , ... benefit services to more than 175,000 BCBSMT,members enrolled in ... covers a range of pharmacy benefit services including:,claims processing, ...
... to drive again , , WEDNESDAY, Dec. 10 (HealthDay News) -- ... after orthopedic surgery or injury, but knowing when it,s safe to ... surgeons weigh in on the issue in the December issue of ... "Deciding when a patient can return to driving is a difficult ...
... density, new analysis shows , , WEDNESDAY, Dec. 10 (HealthDay ... Actos, double the risk of fractures in women but ... Avandia (rosiglitazone) and Actos (pioglitazone) are used to lower ... studies have suggested that the risk for heart failure, ...
... Artist Toni Braxton and Her Son Featured in TV and ... YORK, Dec. 10 The Advertising Council, in partnership with ... of public service advertisements (PSAs) featuring Grammy award-winning recording artist ... about autism and to urge parents to learn the early ...
Cached Medicine News:Health News:Synovics Pharmaceuticals Announces Additional Investment by Svizera and Reduction of Debt 2Health News:Synovics Pharmaceuticals Announces Additional Investment by Svizera and Reduction of Debt 3Health News:Synovics Pharmaceuticals Announces Additional Investment by Svizera and Reduction of Debt 4Health News:Synovics Pharmaceuticals Announces Additional Investment by Svizera and Reduction of Debt 5Health News:Todobebe Rolls Out Embarazo.com for Pregnant Moms 2Health News:Prime Therapeutics Announces Blue Cross and Blue Shield of Montana as a Pharmacy Benefit Services Client 2Health News:Returning to the Road Tricky After Injury 2Health News:2 Diabetes Drugs Double Fracture Risk in Women 2Health News:2 Diabetes Drugs Double Fracture Risk in Women 3Health News:Video: The Advertising Council and Autism Speaks Launch New PSAs to Raise Awareness of Autism 2Health News:Video: The Advertising Council and Autism Speaks Launch New PSAs to Raise Awareness of Autism 3Health News:Video: The Advertising Council and Autism Speaks Launch New PSAs to Raise Awareness of Autism 4
Used to introduce balloon, closed and non-tapered end catheters or other devices for intervention....
Used to introduce balloon, diagnostic and guiding catheters, or other devices for intervention....
Used to introduce large devices for vascular intervention....
Used to introduce balloon, closed and non-tapered end catheters and other devices for intervention....
Medicine Products: